Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
« First ‹ Prev … 170 171 172 173 174 175 176 177 178 … Next › Last »

Advisory Committee Tracker: Anti-Infectives Featured In Unusual Mix Of April Meeting Topics

April 3, 2019

House Insulin Hearing Tees Up Questions For Manufacturers Next Week; Bipartisan Approach By DeGette Offers Relatively Favorable Context For Testimony

April 3, 2019

Prevision Policy Clips | Cigna/Express Scripts Announces $25 Cap on Insulin Ahead of Pharma/PBM Insulin Hearing April 10

April 3, 2019

Rebate Rule Delay Seems Certain Given Absence From Final Medicare Part D Call Letter

April 2, 2019

Interchangeable Insulin: FDA Public Meeting Continues Rhetorical Push – But Underscores Slow Moving Path With Biosimilar Transition

April 2, 2019

Prevision Policy Clips | CREATES, "Pay For Delay" Among Drug Pricing Bills Slated For Markup By Full House E&C Committee on April 3

April 2, 2019

Prevision Policy Clips | GOP Senator Proposes “International Retail List Price Index” Bill

April 1, 2019

Pfizer Looking At Dashboard Updates On Clinical Trial Progress For Patients As One Way To Start Data Sharing

March 29, 2019

Prevision Policy Clips | CMS Implements BBA Change On Medicaid Rebates for Line Extensions, Score Lowered

March 29, 2019

FDA Is Moving Ahead On Comparative Safety, Efficacy Requirement For New Opioids; Gottlieb Says Opioids Demand Higher Standard To Earn Approval

March 28, 2019

CREATES, “Pay-For-Delay” Bills Pass E&C Health Subcommittee As Generic Drug Pricing Responses; Work Will Continue Before Full Committee

March 28, 2019

Prevision Policy Clips | TIRF REMS Requirements Strengthened, More Actions May Be Coming

March 28, 2019

OCE Highlights Importance Of Supportive Data, Early Inclusion Of Patients In Trials At CNS Metastases Product Development Workshop

March 27, 2019

Naloxone Price Negotiation Unnecessary Given Narcan Popularity And Affordability, HHS’ Hargan Testifies To House Budget Committee

March 27, 2019

Prevision Policy Clips | Gilead’s Asegua Authorized Generic Subsidiary Chosen By Louisiana As Hep C Subscription Partner

March 27, 2019

FDA Highlights Best Practices For Natural History Studies And External Controls In Rare Disease Drug Development Guidance

March 26, 2019

Prevision Policy Clips | CREATES Act Among Six Drug Pricing Bills Set For House E&C Markup On March 27

March 26, 2019

Prevision Policy Clips | Senate Appropriations FDA Budget Hearing Thursday

March 25, 2019

Prevision Policy Clips | Chiesi/Pharmaxis Bronchitol For CF Returns To Advisory Committee May 8

March 22, 2019

FDA Reorg: Commissioner’s Office Plan Will Be Implemented As Gottlieb Leaves; Phase One In CDER Revamp Also Ready To Go – But OND Overhaul Still Pending

March 21, 2019

Prevision Policy Clips | Vivitrol For All? OUD Medications Should Be Available For All People

March 21, 2019

Medicaid Rebates On Specialty Drugs Hit 50% Of AMP; Part D Achieved Just 14% Rebates At Retail -- CBO Analysis Shows

March 20, 2019

Prevision Policy Clips | DTC List Price Final Rule Goes To OMB

March 20, 2019

Pediatric HIV Final Guidance Recommends Adolescent Enrollment In Phase III Trials, Neonate Inclusion Based On Older Pediatric Patient Experience

March 19, 2019

Prevision Policy Clips | CBO Specialty Drug Prices & Spending Report

March 19, 2019
« First ‹ Prev … 170 171 172 173 174 175 176 177 178 … Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Copyright © 2026 Prevision Policy. All Rights Reserved. Privacy Policy